文献速递肝胆胰外科围术期管理与 ERAS

肌少性肥胖对肝细胞癌肝切除患者结局的影响

Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma.
PubMed 文献 · Ann Surg · 2019-01-01

该回顾性研究分析了465例2005年4月至2015年3月间因肝细胞癌行初次肝切除的患者,通过术前CT评估骨骼肌质量和内脏脂肪组织,将患者按肌少症和肥胖分为四组。结果显示肌少性肥胖患者中位生存期(39.1 vs. 84.7个月,P=0.002)和无复发生存期(8.4 vs. 21.4个月,P=0.003)均显著差于非肌少非肥胖患者,多因素分析证实肌少性肥胖是死亡(HR=2.504,P=0.005)和复发(HR=2.031,P=0.006)的独立危险因素。

要点

  • 术前CT可评估肌少症和肥胖,肌少性肥胖占肝切除患者的7%。
  • 肌少性肥胖患者中位生存期和无复发生存期显著缩短。
  • 肌少性肥胖是肝切除后死亡和复发的独立危险因素。

核心结论

  • 术前肌少性肥胖是肝细胞癌肝切除后死亡和复发的独立危险因素。

研究设计与样本

  • 回顾性分析465例2005年4月至2015年3月因肝细胞癌行初次肝切除的患者,术前CT评估骨骼肌质量和内脏脂肪组织以定义肌少症和肥胖,按两者有无分为四组。

主要发现

  • 体质构成分组:非肌少非肥胖184例(39%),非肌少肥胖219例(47%),肌少非肥胖31例(7%),肌少性肥胖31例(7%)。
  • 肌少性肥胖组中位生存期39.1个月,非肌少非肥胖组84.7个月(P=0.002)。
  • 肌少性肥胖组中位无复发生存期8.4个月,非肌少非肥胖组21.4个月(P=0.003)。
  • 多因素分析显示肌少性肥胖与死亡风险增加独立相关(HR=2.504,P=0.005)。
  • 多因素分析显示肌少性肥胖与复发风险增加独立相关(HR=2.031,P=0.006)。

临床怎么用

  • 对肝细胞癌拟行肝切除患者,术前可结合CT评估肌少性肥胖以辅助风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate preoperative body composition, including skeletal muscle and visceral adipose tissue, and to clarify the impact on outcomes after hepatectomy for hepatocellular carcinoma (HCC). BACKGROUND: Recent studies have indicated that sarcopenia is associated with morbidity and mortality in various pathologies, including cancer, and that obesity or visceral adiposity represents a significant risk factor for several cancers. However, the impact of sarcopenic obesity on outcomes after hepatectomy for HCC has not been fully investigated. METHODS: We retrospectively analyzed 465 patients who underwent primary hepatectomy for HCC between April 2005 and March 2015. Skeletal muscle mass and visceral adipose tissue were evaluated by preoperative computed tomography to define sarcopenia and obesity. Patients were classified into 1 of 4 body composition groups according to the presence or absence of sarcopenia and obesity. RESULTS: Body composition was classified as nonsarcopenic nonobesity in 184 patients (39%), nonsarcopenic obesity in 219 (47%), sarcopenic nonobesity in 31 (7%), and sarcopenic obesity in 31 (7%). Compared with patients with nonsarcopenic nonobesity, patients with sarcopenic obesity displayed worse median survival (84.7 vs. 39.1 mo, P = 0.002) and worse median recurrence-free survival (21.4 vs. 8.4 mo, P = 0.003). Multivariate analysis identified sarcopenic obesity as a significant risk factor for death (hazard ratio [HR] = 2.504, P = 0.005) and HCC recurrence (HR = 2.031, P = 0.006) after hepatectomy for HCC. CONCLUSION: Preoperative sarcopenic obesity was an independent risk factor for death and HCC recurrence after hepatectomy for HCC.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Kobayashi A, Kaido T, Hamaguchi Y, et al. Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Ann Surg. 2019. PMID: 29064889. doi:10.1097/SLA.0000000000002555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。